Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Vera Therapeutics, Inc.

NASDAQ: VERA · Life Sciences · 3 alerts · CIK 1831828

Share price
$26.97Close, Nov 16
Market cap
$1.95B
Shares outstanding
72.3MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Vera Therapeutics, Inc. filings on SEC EDGAR ↗

6:46 AM ET 8-K
Clinical Trial Data

Vera Therapeutics Clinical Trial Data

Vera Therapeutics announced positive topline results from the final efficacy analysis of its Phase 3 ORIGIN 3 trial of TRUTAKNA (atacicept-vymj) in patients with IgA nephropathy. The trial met all prespecified endpoints, demonstrating a 76% reduction in the risk of kidney disease progression and stabilization of kidney function (eGFR) through 104 weeks. The company plans to submit a supplemental BLA for full FDA approval in the fourth quarter of 2026.

Term
104 weeks

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.